Literature DB >> 28102730

Alloimmunisation in transfused patients: serial cross-matching in a population of hospitalised cats.

Layla Hourani1, Christiane Weingart1, Barbara Kohn1.   

Abstract

Objectives Cross-matching is currently recommended as part of pre-transfusion testing for repeat transfusions in cats 4 days after having received an initial transfusion. This prospective study determined when and if cats developed positive cross-match (CM) results after having been transfused with AB-compatible blood. Methods Donors were selected according to standard transfusion safety protocols. Twenty-one hospitalised anaemic recipients (blood type A: n = 20; blood type B: n = 1) received 1-4 (median 2) whole blood transfusions (WBTs) over 1-6 days (median 2) in 33 transfusion instances. The tube CM method, including major, minor and recipient control, was employed. Macroscopic and microscopic agglutination reactions were evaluated according to a predetermined scale. CM tests with a positive recipient control could not be evaluated. Results No signs of an acute transfusion reaction were observed. A total of 63 CMs were performed. In one cat with immune-mediated haemolytic anaemia the CM could not be evaluated (positive recipient control). The minor CM was negative in all cases. Fifteen of 20 cats had a negative major CM (MCM) 1-12 days (median 5) after their first transfusion. A positive MCM was observed in five cases after 2-10 days (median 5) post-first WBT. These five cats had received a total of 1-4 (median 2) WBTs. Cats with a negative MCM had received 1-3 (median 2) WBTs. In 51.5% (17/33) of transfusion instances, the cat's haematocrit increased as expected, with cats with a positive MCM at 40% (4/10) vs 56.5% (13/23) if MCM was negative. Conclusions and relevance Twenty-five percent (5/20) of the feline recipients likely developed alloantibodies against erythrocyte antigens outside of the AB system as early as 2 days post-first WBT. This adds data to the recommendation to include cross-matching in pre-transfusion screening tests.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28102730     DOI: 10.1177/1098612X16688574

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  6 in total

1.  Detection of naturally occurring alloantibody by an in-clinic antiglobulin-enhanced and standard crossmatch gel column test in non-transfused domestic shorthair cats.

Authors:  Isabelle Goy-Thollot; Alexandra Nectoux; Maryline Guidetti; Benjamin Chaprier; Sarah Bourgeois; Catherine Boisvineau; Anthony Barthélemy; Céline Pouzot-Nevoret; Urs Giger
Journal:  J Vet Intern Med       Date:  2018-12-17       Impact factor: 3.333

2.  Characterization of post-transfusion anti-FEA 1 alloantibodies in transfusion-naive FEA 1-negative cats.

Authors:  Alyssa Cannavino; Dana LeVine; Marie-Claude Blais
Journal:  J Feline Med Surg       Date:  2022-05-05       Impact factor: 1.971

3.  Alloimmunization in dogs after transfusion: A serial cross-match study.

Authors:  Lisa Herter; Christiane Weingart; Nina Merten; Nicole Bock; Roswitha Merle; Barbara Kohn
Journal:  J Vet Intern Med       Date:  2022-08-19       Impact factor: 3.175

4.  Prevalence of naturally occurring non-AB blood type incompatibilities in cats and influence of crossmatch on transfusion outcomes.

Authors:  Megan E McClosky; Dorothy Cimino Brown; Nicole M Weinstein; Nicole Chappini; Michael T Taney; Kimberly Marryott; Mary Beth Callan
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

5.  Assessment of risks of feline mismatched transfusion and neonatal isoerythrolysis in the Lyon (France) area.

Authors:  Alexandra Nectoux; Maryline Guidetti; Anthony Barthélemy; Céline Pouzot-Nevoret; Guillaume L Hoareau; Isabelle Goy-Thollot
Journal:  JFMS Open Rep       Date:  2019-07-22

6.  Identification of 5 novel feline erythrocyte antigens based on the presence of naturally occurring alloantibodies.

Authors:  Marie Binvel; Julie Arsenault; Boris Depré; Marie-Claude Blais
Journal:  J Vet Intern Med       Date:  2020-12-18       Impact factor: 3.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.